denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Bleeding and Clotting, Clinical Practice (Health Services and Quality), Workforce, Diversity, Equity, and Inclusion (DEI) , thromboembolism, drug development, Diseases, drug-drug interactions, Therapies, thrombotic disorders, Study Population
Description:
Venous thromboembolism (VTE) is a leading cause of cardiovascular diseases and related mortality. The optimal prevention and treatment strategies for VTE are essential. The development and generalization of direct oral anticoagulants have significantly advanced the field in recent years. Novel anticoagulants that could potentially provide improved safety are on the horizon. This educational session will first address common questions regarding frequently used oral factor Xa inhibitors by reviewing current literature and providing evidence-based suggestions. Next, controversies and recommendations of optimal VTE prevention strategies for hospitalized medical patients including those with COVID-19 will be discussed. Lastly, the session will explore the upcoming new anticoagulants and strategies for prevention and treatment of VTE, including factor XI inhibitors.
Dr. Tzu-Fei Wang will address five commonly asked questions regarding the use of oral factor Xa inhibitors for the treatment of VTE, including obesity, renal impairment, gastrointestinal malignancy, catheter-related thrombosis, and drug-drug interactions. For each topic, the scope of the problem and pertinent literature will be reviewed. Available guidelines and practice approaches will be discussed.
Dr. Alex Spyropoulos will discuss four controversial topics in thromboprophylaxis of hospitalized acutely-ill medical patients: 1) clinical relevance of key efficacy and safety outcomes incorporated into randomized trials but not incorporated into antithrombotic guidelines on the topic, 2) establishment of individual risk factors or risk models of low bleed risk and high thrombotic risk subgroups of medically ill inpatients that benefit from extended thromboprophylaxis, 3) the use of mechanical thromboprophylaxis in this population, and 4) thromboprophylaxis of hospitalized COVID-19 patients, a high thrombotic risk subset of medically-ill patients. The clinical and populational health effects of these issues will be discussed, as well implications for future antithrombotic guidelines on these topics.
Dr. Walter Ageno’s talk will initially focus on the unmet clinical needs in the prevention and treatment of venous and arterial thromboembolic disorders. In particular, the difficult management of patients at high risk of bleeding will be briefly discussed. This will provide the background for the development of new classes of anticoagulant drugs, aimed at maximizing antithrombotic efficacy while minimizing the risk of bleeding. Molecules targeting Factor XI and Factor XII currently under development will be presented and the results of the first published studies will be commented. Finally, potential implications for clinical practice and additional areas of research for these new drugs will be discussed.
Dr. Tzu-Fei Wang will address five commonly asked questions regarding the use of oral factor Xa inhibitors for the treatment of VTE, including obesity, renal impairment, gastrointestinal malignancy, catheter-related thrombosis, and drug-drug interactions. For each topic, the scope of the problem and pertinent literature will be reviewed. Available guidelines and practice approaches will be discussed.
Dr. Alex Spyropoulos will discuss four controversial topics in thromboprophylaxis of hospitalized acutely-ill medical patients: 1) clinical relevance of key efficacy and safety outcomes incorporated into randomized trials but not incorporated into antithrombotic guidelines on the topic, 2) establishment of individual risk factors or risk models of low bleed risk and high thrombotic risk subgroups of medically ill inpatients that benefit from extended thromboprophylaxis, 3) the use of mechanical thromboprophylaxis in this population, and 4) thromboprophylaxis of hospitalized COVID-19 patients, a high thrombotic risk subset of medically-ill patients. The clinical and populational health effects of these issues will be discussed, as well implications for future antithrombotic guidelines on these topics.
Dr. Walter Ageno’s talk will initially focus on the unmet clinical needs in the prevention and treatment of venous and arterial thromboembolic disorders. In particular, the difficult management of patients at high risk of bleeding will be briefly discussed. This will provide the background for the development of new classes of anticoagulant drugs, aimed at maximizing antithrombotic efficacy while minimizing the risk of bleeding. Molecules targeting Factor XI and Factor XII currently under development will be presented and the results of the first published studies will be commented. Finally, potential implications for clinical practice and additional areas of research for these new drugs will be discussed.